Your browser doesn't support javascript.
loading
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Cirrincione, Anthony M; Poos, Alexandra M; Ziccheddu, Bachisio; Kaddoura, Marcella; Bärtsch, Marc-Andrea; Maclachlan, Kylee; Chojnacka, Monika; Diamond, Benjamin; John, Lukas; Reichert, Philipp; Huhn, Stefanie; Blaney, Patrick; Gagler, Dylan; Rippe, Karsten; Zhang, Yanming; Dogan, Ahmet; Lesokhin, Alexander M; Davies, Faith; Goldschmidt, Hartmut; Fenk, Roland; Weisel, Katja C; Mai, Elias K; Korde, Neha; Morgan, Gareth J; Usmani, Saad; Landgren, Ola; Raab, Marc S; Weinhold, Niels; Maura, Francesco.
Afiliación
  • Cirrincione AM; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
  • Poos AM; Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Ziccheddu B; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Kaddoura M; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
  • Bärtsch MA; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
  • Maclachlan K; Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Chojnacka M; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Diamond B; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • John L; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
  • Reichert P; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
  • Huhn S; Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Blaney P; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Gagler D; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Rippe K; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Zhang Y; Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
  • Dogan A; Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
  • Lesokhin AM; Division of Chromatin Networks, German Cancer Research Center and BioQuant, Heidelberg, Germany.
  • Davies F; Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Goldschmidt H; Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Fenk R; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Weisel KC; Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
  • Mai EK; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Korde N; Department of Hematology, Oncology and Clinical Immunology, University-Hospital Duesseldorf, Duesseldorf, Germany.
  • Morgan GJ; Department of Oncology, Hematology, and Blood and Marrow Transplant, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Usmani S; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Landgren O; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Raab MS; Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
  • Weinhold N; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Maura F; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Blood ; 144(7): 771-783, 2024 Aug 15.
Article en En | MEDLINE | ID: mdl-38728430
ABSTRACT
ABSTRACT Acquisition of a hyperdiploid (HY) karyotype or immunoglobulin heavy chain (IgH) translocations are considered key initiating events in multiple myeloma (MM). To explore if other genomic events can precede these events, we analyzed whole-genome sequencing data from 1173 MM samples. By integrating molecular time and structural variants within early chromosomal duplications, we indeed identified pregain deletions in 9.4% of patients with an HY karyotype without IgH translocations, challenging acquisition of an HY karyotype as the earliest somatic event. Remarkably, these deletions affected tumor suppressor genes (TSGs) and/or oncogenes in 2.4% of patients with an HY karyotype without IgH translocations, supporting their role in MM pathogenesis. Furthermore, our study points to postgain deletions as novel driver mechanisms in MM. Using multiomics approaches to investigate their biologic impact, we found associations with poor clinical outcome in newly diagnosed patients and profound effects on both the oncogene and TSG activity despite the diploid gene status. Overall, this study provides novel insights into the temporal dynamics of genomic alterations in MM.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Female / Humans / Male Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Female / Humans / Male Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article